Nasus Pharma Ltd. (NSRX) - Total Liabilities
Based on the latest financial reports, Nasus Pharma Ltd. (NSRX) has total liabilities worth $2.24 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nasus Pharma Ltd. - Total Liabilities Trend (2022–2025)
This chart illustrates how Nasus Pharma Ltd.'s total liabilities have evolved over time, based on quarterly financial data. See Nasus Pharma Ltd. (NSRX) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Nasus Pharma Ltd. Competitors by Total Liabilities
The table below lists competitors of Nasus Pharma Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Uniti SA
PA:ALUNT
|
France | €284.01 Million |
|
Pan Brothers Tbk
JK:PBRX
|
Indonesia | Rp130.50 Million |
|
DKLS Industries Bhd
KLSE:7528
|
Malaysia | RM54.33 Million |
|
Shandong Chenming Paper Holdings Limited
F:SCD1
|
Germany | €48.86 Billion |
|
SWISS PROPERTIES INV.100
F:SR1
|
Germany | €454.08 Million |
|
Dr Peng Telecom and Media Group Co Ltd
SHG:600804
|
China | CN¥7.58 Billion |
|
HCT Co. Ltd
KQ:072990
|
Korea | ₩82.24 Billion |
|
Risma Systems AS
CO:RISMA
|
Denmark | Dkr34.76 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down Nasus Pharma Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Nasus Pharma Ltd. market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nasus Pharma Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nasus Pharma Ltd. (2022–2025)
The table below shows the annual total liabilities of Nasus Pharma Ltd. from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.24 Million | -43.09% |
| 2024-12-31 | $3.93 Million | -7.36% |
| 2023-12-31 | $4.24 Million | +32.45% |
| 2022-12-31 | $3.20 Million | -- |
About Nasus Pharma Ltd.
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS00… Read more